This activity has been designed to meet the educational needs of medical, surgical and radiation oncologists, registered nurses and other medical professionals involved in the treatment of breast cancer.
LEARNING OBJECTIVES :
Upon completion of this activity, participants should be able to:
- Select appropriate regimens for the medical management of early breast cancer considering key clinical and pathologic risk factors.
- Develop treatment plans for patients with early and advanced HER2-positive breast cancer based on the risk-benefit profile of evidence-based HER2-directed agents and the impact of concurrent cytotoxic chemotherapy and endocrine therapies.
- Incorporate biologic and molecular-targeted therapies in the adjuvant and metastatic settings for appropriately selected patients with breast cancer.
- Assess the emerging role of adjuvant bisphosphonates in the management of early breast cancer, and identify patients that may benefit from this treatment approach.
- Review the research supporting the activity of various chemotherapeutic approaches for early and advanced breast cancer, including the contributing roles of taxanes and anthracyclines, and explain the absolute risks and benefits of these regimens to patients.
- Counsel appropriately selected patients about the availability of ongoing clinical trial participation.
- Explain the value of tissue-based genomic assays in the care of patients with early breast cancer and, when applicable, use these in the selection of individualized treatment regimens.
- Apply existing data and emerging research on the optimal duration and sequence of adjuvant endocrine therapy for hormone receptor-positive breast cancer to current patient care decisions.
- Consider the special needs of patients who are pregnant or are seeking options to preserve fertility when developing treatment algorithms for women with early breast cancer.
ACCREDITATION STATEMENT:
Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
CREDIT DESIGNATION STATEMENT:
CME: Research To Practice designates this educational activity for a maximum of 2.25 AMA PRA Category 1 Credits™. Physicians should only claim credit commensurate with the extent of their participation in the activity.
CNE: This educational activity for 2.25 contact hours is provided by Research To Practice, an approved provider of continuing nursing education by the New Jersey State Nurses Association, Provider Number P215-01/07-10. NJSNA is accredited by the ANCC Commission on Accreditation. Provider Approval is valid through January 31, 2010.
UNLABELED / UNAPPROVED USES NOTICE
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the sponsor or grantors.
CONTENT VALIDATION AND DISCLOSURES
Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education. We assess potential conflicts of interest with faculty, planners and managers of CME/CNE activities. Real or apparent conflicts of interest are identified and resolved through a conflict of interest resolution process. In addition, all activity content is reviewed by both a member of the RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.
MODERATOR — Dr Love does not receive any direct remuneration from industry. Research To Practice receives funds in the form of educational grants to develop CME activities from the following commercial interests: Abraxis BioScience, AstraZeneca Pharmaceuticals LP, Aureon Laboratories Inc, Bayer Pharmaceuticals Corporation/Onyx Pharmaceuticals Inc, Biogen Idec, Bristol-Myers Squibb Company, Celgene Corporation, Centocor Ortho Biotech Services, Eli Lilly and Company, Genentech BioOncology, Genomic Health Inc, GlaxoSmithKline, ImClone Systems Incorporated, Merck and Company Inc, MGI Pharma Inc, Millennium Pharmaceuticals, The Takeda Oncology Company, Novartis Pharmaceuticals Corporation, OSI Oncology, Pfizer Inc, Roche Laboratories Inc, Sanofi-Aventis, Synta Pharmaceuticals Corp and Wyeth.
FACULTY — Dr Allison had no real or apparent conflicts of interest to disclose. The following faculty (and their spouses/partners) reported real or apparent conflicts of interest, which have been resolved through a conflict of interest resolution process:
Dr Astrow — Consulting Agreement: Pfizer Inc.
Dr Burris — Consulting Agreements: Bristol-Myers Squibb Company, Celgene Corporation, Genentech BioOncology, GlaxoSmithKline, ImClone Systems Incorporated, Novartis Pharmaceuticals Corporation, Roche Laboratories Inc, Sanofi-Aventis.
Prof Crown — Speakers Bureau: GlaxoSmithKline, Pfizer Inc, Sanofi-Aventis.
Dr Fox — Consulting Agreement: Novartis Pharmaceuticals Corporation; Paid Research: GlaxoSmithKline; Speakers Bureau: AstraZeneca Pharmaceuticals LP, Bristol-Myers Squibb Company, Eli Lilly and Company, Genentech BioOncology, Genomic Health Inc, GlaxoSmithKline, Roche Laboratories Inc.
Dr Gralow — Consulting Agreements: Amgen Inc, Genentech BioOncology, Genomic Health Inc, GlaxoSmithKline, Novartis Pharmaceuticals Corporation, Roche Laboratories Inc, Sanofi-Aventis.
Dr Hudis — Advisory Committee: Amgen Inc, GlaxoSmithKline, Novartis Pharmaceuticals Corporation, Pfizer Inc, Sanofi-Aventis; Consulting Agreements: Bristol-Myers Squibb Company, Genentech BioOncology, Wyeth; Paid Research: AstraZeneca Pharmaceuticals LP, Onyx Pharmaceuticals Inc, Roche Laboratories Inc; Stock Ownership: Genomic Health Inc.
Dr Moss — Advisory Committee: Celgene Corporation, Millennium Pharmaceuticals, The Takeda Oncology Company, Pharmion Corporation; Paid Research: Abraxis BioScience, Amgen Inc, Archimedes Development Limited, Centocor Ortho Biotech Services, Eisai Inc, Genentech BioOncology, Pharmatech Inc, Sanofi-Aventis, Taiho Pharmaceutical Co Ltd, Wyeth.
Dr Wolff — Paid Research: Roche Laboratories Inc.
RESEARCH TO PRACTICE STAFF AND EXTERNAL REVIEWERS — The scientific staff and reviewers for Research To Practice have no real or apparent conflicts of interest to disclose.
